雌激素与贝伐单抗等因子对SKBR-3乳腺癌细胞VEGF表达影响观察

目的：观察不同浓度雌激素对SKBR-3乳腺癌细胞血管内皮生长因子（vascularendothelialgrowthfactor，VEGF）表达的影响，并探讨不同浓度雌激素作用条件下，贝伐单抗（VEGF单抗）、曲妥珠单抗（HER-2单抗）、紫杉醇和胰岛素样生长因子1受体（insulin-likegrowthfactorreceptor，IGF-1R）抗体对SKBR-3乳腺癌细胞VEGF表达的影响。方法：利用RT-PCR方法检测SKBR-3乳腺癌细胞在不同浓度雌激素以及VEGF单抗（0．5μg／mL）、HER-2单抗（0．04μg／mL）、紫杉醇（1．5μg／mL）和IGF-1R抗体（2．5μg／mL）作用下，SKBR-3乳腺癌细胞VEGF的表达状况，利用ELISA方法检测培养液上清中VEGF蛋白浓度。结果：1）无雌激素组SKBR-3乳腺癌细胞VEGF表达为1．0618±0．0085（vEGF／GAPDH，下同），低浓度雌激素（0．05μg／mL，）组为1．0047±0．0061，差异有统计学意义，P=0．002，高浓度雌激素（O．2μg／mL）组为1．0868±0．0135，差异有统计学意义，P〈0．001。2）用与不用紫杉醇SKBR-3乳腺癌细胞VEGF表达分别为1．0496±0．0288和1．0618±0．0085，F=0．058；用与不用IGF=1R单抗为1．0884±0．0036和1．06184-0．0085，F=0．073；用与不用HER-2单抗分别为0．9887±0．0037和1．0618±0．0085，F=0．075；同时，在应用紫杉醇、IGF1R单抗、HER-2单抗基础上加用雌激素VEGF表达不受影响。3）用与不用VEGF单抗SKBR-3乳腺癌细胞VEGF表达分别为1．0057±0．0043、1．0618±0．0085，差异有统计学意义，F=0．132，P=0．04；但雌激素与VEGF单抗对VEGF表达影响没有协同作用。结论：不同雌激素浓度对SKBR-3乳腺癌细胞VEGF表达影响明显；紫杉醇、IGF-1R单抗和HER-2单抗不影响SKBR3乳腺癌细胞VEGF表达，与雌激素也无协同作用；VEGF单抗升高VEGF表达，也与雌激素没有协同作用。

Influence of estrogen,Bevacizumab on VEGF expression of SKBR-3 breast cancer cells

OBJECTIVE： To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab,Trastuzumab,Taxol and IGF-1R antibody treatment in different estrogen. METHODS： We examined VEGF-expression of the SKBR-3 breast cancer cells aftel： different cancentration of estrogen, Arastin, H erceptin, Taxoland IGF-1R antibody with RT-PCR. VEGF protein in supernate was detected by ELE- SA. RESULTS： The expression of VEGF in conto group was 1. 061 80. 008 5 （VEGF/GAPDH） ,the expression of VEGF in low concentration group（50 μg/L） was 1. 004 7 ± 0. 006 1 （P= 0. 002）, the expression of VEGF in high concentration group （0.2 μg/mL） was 1. 086 8-1-0. 013 5（P〈0. 001）. The expression of VEGF were 1. 049 6±0. 028 8 and 1. 061 8±0. 008 5 in Taxol group and contral group（F= 0. 058） ,the expression of VEGF were 1. 088 4 ± 0. 003 6,1. 061 8 ± 0. 008 5 in antibody of IGF-1R group and contral group（ F= 0. 073）, the expression of VEGF were 0. 988 7 ± 0. 003 7,1. 061 8 ± 0. 008 5 in Trastuzumab group and contral group（F=0. 075）. There were no change of VEGF expression in Taxol group, antibody of IGF1R group and Trastuzumab group with estrogen. The expression of VEGF were 1. 005 7±0. 004 3 and 1. 061 8±0. 008 5 in Bevacizumab group and eontral group（F=0. 132, P= 0. 004） and estrogen had no influence on the action. CONCLUSIONS： The influence of different estrogen on VEGF expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells and estrogen had no influence to this action. Bevacizumab increases the expression of VEGF and estrogen do not change the action.